Base de dados : MEDLINE
Pesquisa : C04.588.180.260 [Categoria DeCS]
Referências encontradas : 2649 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 265 ir para página                         

  1 / 2649 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29204896
[Au] Autor:Streng M; Ignatov A; Reinisch M; Costa SD; Eggemann H
[Ad] Endereço:Department of Obstetrics and Gynecology, University of Magdeburg, Magdeburg, Germany.
[Ti] Título:A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study.
[So] Source:J Cancer Res Clin Oncol;144(2):381-387, 2018 Feb.
[Is] ISSN:1432-1335
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Precise presurgical diagnosis of tumour size is essential for adequate treatment of male breast cancer (MBC). This study is aimed to compare the accuracy of clinical measurement (CE), ultrasound (US) and mammography (MG) for preoperative estimation of tumour size. METHODS: This study was conducted as a prospective, multicentre register study. One hundred and twenty-nine male patients with invasive breast cancer were included. CE, US and MG were performed in 107, 110 and 75 patients, respectively, and the estimated tumour size was compared with the histopathological (HP) tumour size. RESULTS: All methods tended to underestimate the HP tumour size. None of the methods were significantly more accurate than the others in determining the maximal tumour diameter. The sensitivity within 5 mm tolerance for US was 65.5%, which was better than for MG (61.3%) and CE (56.6%). In the group of patients with pT2 tumours, MG showed significantly better accuracy than US. The measurements obtained with each method were significantly correlated with the HP measurements. The highest correlation coefficient was observed for MG (0.788), followed by US (0.741) and CE (0.671). CONCLUSIONS: Our data demonstrate that MG and US have similar accuracy with regard to tumour size estimation. US assessment showed the highest sensitivity in determining tumour size, followed by MG and CE. However, MG demonstrated a significant advantage for estimating the real tumour size for pT2 tumours compared to US or CE.
[Mh] Termos MeSH primário: Neoplasias da Mama Masculina/diagnóstico
Neoplasias da Mama Masculina/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama Masculina/diagnóstico por imagem
Neoplasias da Mama Masculina/epidemiologia
Alemanha/epidemiologia
Seres Humanos
Masculino
Mamografia
Meia-Idade
Palpação
Estudos Prospectivos
Sistema de Registros
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1007/s00432-017-2554-8


  2 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470916
[Au] Autor:Obata A; Okauchi S; Kimura T; Hirukawa H; Tanabe A; Kinoshita T; Kohara K; Tatsumi F; Shimoda M; Kamei S; Nakanishi S; Mune T; Kaku K; Kaneto H
[Ad] Endereço:Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
[Ti] Título:Advanced breast cancer in a relatively young man with severe obesity and type 2 diabetes mellitus.
[So] Source:J Diabetes Investig;8(3):395-396, 2017 May.
[Is] ISSN:2040-1124
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:It is known that male breast cancer is extremely rare and obesity is a strong risk factor of breast cancer in both male and female. In general, the prognosis in breast cancer in males is known to be very poor compared to that in females as it tends to be more advanced stage due to delayed initial diagnosis. Therefore, we should be aware of the possibility that breast cancer could be developed even in relatively young males without any specific risk factors especially when the subjects have severe obesity.
[Mh] Termos MeSH primário: Neoplasias da Mama Masculina/complicações
Neoplasias da Mama Masculina/diagnóstico
Diabetes Mellitus Tipo 2/complicações
Obesidade Mórbida/complicações
[Mh] Termos MeSH secundário: Adulto
Neoplasias da Mama Masculina/patologia
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/jdi.12570


  3 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463158
[Au] Autor:Abrams MJ; Koffer PP; Wazer DE; Hepel JT
[Ad] Endereço:Department of Radiation Oncology, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts. Electronic address: mabrams@tuftsmedicalcenter.org.
[Ti] Título:Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):384-391, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Because of its rarity, there are no randomized trials investigating postmastectomy radiation therapy (PMRT) in male breast cancer. This study retrospectively examines the impact of PMRT in male breast cancer patients in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. METHODS AND MATERIALS: The SEER database 8.3.2 was queried for men ages 20+ with a diagnosis of localized or regional nonmetastatic invasive ductal/lobular carcinoma from 1998 to 2013. Included patients were treated by modified radical mastectomy (MRM), with or without adjuvant external beam radiation. Univariate and multivariate analyses evaluated predictors for PMRT use after MRM. Kaplan-Meier overall survival (OS) curves of the entire cohort and a case-matched cohort were calculated and compared by the log-rank test. Cox regression was used for multivariate survival analyses. RESULTS: A total of 1933 patients were included in the unmatched cohort. There was no difference in 5-year OS between those who received PMRT and those who did not (78% vs 77%, respectively, P=.371); however, in the case-matched analysis, PMRT was associated with improved OS at 5 years (83% vs 54%, P<.001). On subset analysis of the unmatched cohort, PMRT was associated with improved OS in men with 1 to 3 positive nodes (5-year OS 79% vs 72% P=.05) and those with 4+ positive nodes (5-year OS 73% vs 53% P<.001). On multivariate analysis of the unmatched cohort, independent predictors for improved OS were use of PMRT: HR=0.551 (0.412-0.737) and estrogen receptor-positive disease: HR=0.577 (0.339-0.983). Predictors for a survival detriment were higher grade 3/4: HR=1.825 (1.105-3.015), larger tumor T2: HR=1.783 (1.357-2.342), T3/T4: HR=2.683 (1.809-3.978), higher N-stage: N1 HR=1.574 (1.184-2.091), N2/N3: HR=2.328 (1.684-3.218), black race: HR=1.689 (1.222-2.336), and older age 81+: HR=4.164 (1.497-11.582). CONCLUSIONS: There may be a survival benefit with the addition of PMRT for male breast cancer with node-positive disease.
[Mh] Termos MeSH primário: Neoplasias da Mama Masculina/mortalidade
Neoplasias da Mama Masculina/radioterapia
Carcinoma Ductal de Mama/mortalidade
Carcinoma Ductal de Mama/radioterapia
Carcinoma Lobular/mortalidade
Carcinoma Lobular/radioterapia
Linfonodos/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Análise de Variância
Neoplasias da Mama Masculina/patologia
Neoplasias da Mama Masculina/cirurgia
Carcinoma Ductal de Mama/patologia
Carcinoma Ductal de Mama/cirurgia
Carcinoma Lobular/patologia
Carcinoma Lobular/cirurgia
Terapia Combinada/métodos
Terapia Combinada/mortalidade
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Mastectomia Radical Modificada
Meia-Idade
Período Pós-Operatório
Radioterapia Adjuvante/mortalidade
Receptores Estrogênicos/análise
Receptores de Progesterona/análise
Estudos Retrospectivos
Programa de SEER
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Estrogen); 0 (Receptors, Progesterone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  4 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390502
[Au] Autor:Xu R; Li J; Zhang Y; Jing H; Zhu Y
[Ad] Endereço:Medicine and Life Sciences College of Shandong Academy of Medical Sciences, University of Jinan.
[Ti] Título:Male occult breast cancer with axillary lymph node metastasis as the first manifestation: A case report and literature review.
[So] Source:Medicine (Baltimore);96(51):e9312, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Occult breast cancer (OBC) is extremely rare in males with neither symptoms in the breast nor abnormalities upon imaging examination. PATIENT CONCERNS: This current case report presents a young male patient who was diagnosed with male OBC first manifesting as axillary lymph node metastasis. The physical and imaging examination showed no primary lesions in either breasts or in other organs. DIAGNOSES: The pathological results revealed infiltrating ductal carcinoma in the axillary lymph nodes. Immunohistochemical (IHC) staining was negative for estrogen receptor (ER), progesterone receptor (PR), cytokeratin (CK)20 and thyroid transcription factor-1 (TTF-1), positive for CK7, gross cystic disease fluid protein-15 (GCDFP-15), epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA), and suspicious positive for human epidermal receptor-2 (Her-2). On basis of IHC markers, particularly such as CK7, CK20 and GCDFP-15, and eliminating other malignancies, male OBC was identified in spite of negativity for hormone receptors. INTERVENTIONS: The patient underwent left axillary lymph node dissection (ALND) but not mastectomy. After the surgery, the patient subsequently underwent chemotherapy and radiotherapy. OUTCOMES: The patient is currently being followed up without any signs of recurrence. LESSONS: Carefully imaging examination and pathological analysis were particularly essential in the diagnosis of male OBC. The guidelines for managing male OBC default to those of female OBC and male breast cancer.
[Mh] Termos MeSH primário: Axila
Neoplasias da Mama Masculina/patologia
Carcinoma Ductal de Mama/patologia
Metástase Linfática
Neoplasias Primárias Desconhecidas/patologia
[Mh] Termos MeSH secundário: Adulto
Axila/diagnóstico por imagem
Axila/patologia
Neoplasias da Mama Masculina/diagnóstico por imagem
Neoplasias da Mama Masculina/terapia
Carcinoma Ductal de Mama/diagnóstico por imagem
Carcinoma Ductal de Mama/terapia
Seres Humanos
Excisão de Linfonodo
Masculino
Neoplasias Primárias Desconhecidas/diagnóstico por imagem
Neoplasias Primárias Desconhecidas/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009312


  5 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Colômbia
Texto completo SciELO Saúde Pública
[PMID]:28453098
[Au] Autor:González-Mariño MA
[Ad] Endereço:Facultad de Medicina, Universidad Nacional de Colombia, San Martín, Colombia.
[Ti] Título:[Causes of death from breast cancer in Colombia].
[Ti] Título:Causas de muerte por cáncer de mama en Colombia..
[So] Source:Rev Salud Publica (Bogota);18(3):344-353, 2016 Jun.
[Is] ISSN:0124-0064
[Cp] País de publicação:Colombia
[La] Idioma:spa
[Ab] Resumo:Objective To review the direct causes of death from breast cancer in Colombia according to data from death certificates in 2008. Material and Methods We reviewed the direct causes of death in patients whose code of underlying cause of death was malignant tumor of the breast according to the National Statistics Department of Colombia's (DANE from Spanish initials) records of death in 2008. Distribution is evaluated by diagnostic code, age, educational level, marital status, social security and place of death. Results In women, the main direct causes of death were respiratory insufficiency or failure, cardiac arrest, multiple or multisystem organ failure, breast cancer and metastatic breast cancer. Most of the death codes were C509 and they were issued for women over 50 years. In men, the most common cause was respiratory failure. Conclusions The main denominations listed on death records as a direct cause of death from breast cancer were respiratory failure and arrest and cardiopulmonary arrest. However, it is evident that this arises from problems in the registry that are the result of not following the International Classification of Diseases (ICD-10). Improving the quality of death records is required so that all the information given by the death certificates can be used more effectively.
[Mh] Termos MeSH primário: Neoplasias da Mama/mortalidade
[Mh] Termos MeSH secundário: Adulto
Distribuição por Idade
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama Masculina/mortalidade
Causas de Morte
Colômbia/epidemiologia
Atestado de Óbito
Feminino
Parada Cardíaca/mortalidade
Seres Humanos
Masculino
Meia-Idade
Insuficiência Respiratória/mortalidade
Distribuição por Sexo
Fatores Socioeconômicos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  6 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310379
[Au] Autor:Liu J; Wei H; Zhu K; Lai L; Han X; Yang Y
[Ad] Endereço:Department of Pathology, the TongDe Hospital of Zhejiang Province.
[Ti] Título:Male breast cancer and mantle cell lymphoma in a single patient: A case report and literature review.
[So] Source:Medicine (Baltimore);96(48):e8911, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Although still relatively rare, multiple primary malignant neoplasms (MPMNs) have been increasingly reported in recent years. PATIENT CONCERNS AND DIAGNOSES: A 65-year-old man was referred to our hospital for a painless, incidental left axillary lump. Ultrasound showed enlarged left axillary lymph nodes. An excisional biopsy was conducted on 3 lymph nodes. The pathological diagnosis was determined to be metastatic adenocarcinoma and mantle cell lymphoma (MCL) in the lymph nodes. Further physical examination of the patient yielded a 1.5-cm hard, left subareolar mass. INTERVENTIONS AND OUTCOMES: The patient underwent modified radical mastectomy. The diagnosis was grade II invasive ductal carcinoma (stage IIA). The axillary lymph node showed MCL (stage I, group A), but not metastatic ductal carcinoma. The patient received chemotherapy, including 6 courses of CHOP (A chemotherapy protocol consists of cyclophosphamide 1.2 g day 1, doxorubicin 80 mg day 1, vindesine 4 mg day1, and prednisone 90 mg from day 1 to 5) for lymphoma and breast cancer. The patient was also administered endocrine therapy. After a 54-month follow-up, the patient was well with no evidence of disease. LESSONS: MPMNs are easily misdiagnosed as a primary and metastatic tumor, leading to delayed or erroneous treatment. Male breast cancer in a patient with MCL is rare. Early diagnosis and proper therapy are necessary for an optimal prognosis. Further studies are required to define the mechanisms and risk factors of MPMNs.
[Mh] Termos MeSH primário: Adenocarcinoma/patologia
Neoplasias da Mama Masculina/patologia
Linfoma de Célula do Manto/patologia
Neoplasias Primárias Múltiplas/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma/tratamento farmacológico
Adenocarcinoma/cirurgia
Idoso
Biópsia
Neoplasias da Mama Masculina/tratamento farmacológico
Neoplasias da Mama Masculina/cirurgia
Terapia Combinada
Seres Humanos
Linfoma de Célula do Manto/tratamento farmacológico
Linfoma de Célula do Manto/cirurgia
Masculino
Mastectomia
Gradação de Tumores
Neoplasias Primárias Múltiplas/tratamento farmacológico
Neoplasias Primárias Múltiplas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008911


  7 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277752
[Au] Autor:Jardel P; Vignot S; Cutuli B; Creisson A; Vass S; Barranger E; Thariat J
[Ad] Endereço:Department of Radiation Oncology, Chicoutimi Hospital, Saguenay, QC, Canada.
[Ti] Título:Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review.
[So] Source:Anticancer Res;38(1):23-31, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Guidelines for radiotherapy in male breast cancer (MBC) are lacking. Some extrapolate the results from female breast cancer trials, while others advocate systematic adjuvant irradiation. We evaluated clinical practices and outcomes with respect to radiation therapy in MBC treated with locoregional irradiation in the adjuvant setting using a systematic literature review. MATERIAL AND METHODS: We included studies with data about adjuvant radiotherapy published between 1984 and 2017 and including at least 40 patients. RESULTS: We found 29 retrospective series, 10,065 men were diagnosed with breast cancer; 3-100% (mean=54%) received adjuvant radiotherapy. Tumor size and nodal involvement were the strongest prognostic factors. Approximatively half of all cases had nodal metastases. Radiation therapy improved locoregional control in six series, overall survival in three and distant metastasis-free survival in one. CONCLUSION: MBC is diagnosed at a highly advanced stage and may be linked with poorer outcomes. Adjuvant radiation therapy must, at least, be proposed to men with positive nodes. Despite the large number of cases gathered here, arguments for radiotherapy in other prognostic subgroups (especially in pN0) may exist but are not well supported.
[Mh] Termos MeSH primário: Neoplasias da Mama Masculina/radioterapia
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Radioterapia Adjuvante
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  8 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29072945
[Au] Autor:Rosen LE; Gattuso P
[Ad] Endereço:From the Department of Pathology, The University of Chicago Medicine, Chicago, Illinois (Dr Rosen); and the Department of Pathology, Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois (Dr Gattuso).
[Ti] Título:Neuroendocrine Tumors of the Breast.
[So] Source:Arch Pathol Lab Med;141(11):1577-1581, 2017 Nov.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary neuroendocrine tumors of the breast are a rare and underrecognized subtype of mammary carcinoma. Neuroendocrine tumors of the breast occur predominately in postmenopausal women. The tumors are subclassified into well-differentiated and poorly differentiated neuroendocrine tumors, and invasive breast carcinoma with neuroendocrine features. Well-differentiated tumors show architectural similarity to carcinoids of other sites but lack characteristic neuroendocrine nuclei. Poorly differentiated neuroendocrine tumors are morphologically identical to small cell carcinoma of the lung. Neuroendocrine differentiation, seen in up to 30% of invasive breast carcinomas, is most commonly associated with mucinous and solid papillary carcinomas. The diagnosis of neuroendocrine differentiation requires expression of the neuroendocrine markers synaptophysin or chromogranin. The main differential diagnosis is a metastatic neuroendocrine tumor from an extramammary site. Neuroendocrine tumors of the breast are treated similarly to other invasive breast carcinomas. Although no consensus has been reached on the prognosis, most studies suggest a poor outcome.
[Mh] Termos MeSH primário: Neoplasias da Mama/diagnóstico
Carcinoma Neuroendócrino/diagnóstico
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/metabolismo
Neoplasias da Mama/patologia
Neoplasias da Mama/terapia
Neoplasias da Mama Masculina/diagnóstico
Neoplasias da Mama Masculina/metabolismo
Neoplasias da Mama Masculina/patologia
Neoplasias da Mama Masculina/terapia
Carcinoma Neuroendócrino/metabolismo
Carcinoma Neuroendócrino/patologia
Carcinoma Neuroendócrino/terapia
Diferenciação Celular
Cromogranina A/metabolismo
Diagnóstico Diferencial
Feminino
Seres Humanos
Masculino
Gradação de Tumores
Estadiamento de Neoplasias
Prognóstico
Sinaptofisina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CHGA protein, human); 0 (Chromogranin A); 0 (SYP protein, human); 0 (Synaptophysin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171027
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2016-0364-RS


  9 / 2649 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28857013
[Au] Autor:Ahmadinejad F; Mowla SJ; Honardoost MA; Arjenaki MG; Moazeni-Bistgani M; Kheiri S; Teimori H
[Ad] Endereço:1 Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
[Ti] Título:Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis.
[So] Source:Tumour Biol;39(8):1010428317698362, 2017 Aug.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Breast cancer is considered as the most prevalent malignancy in women worldwide. Despite emergence of several prognosticators for better management of patients, there are still limitations for their clinical application due to the complexity of breast tumors, and therefore, new biomarkers for better prognosis of clinical outcomes would be of the great essence. MicroRNAs are highly conserved small non-coding regulatory RNAs involved in post-transcriptional regulating of gene expression during different cellular mechanisms. Accumulating studies suggest that miR-218 plays a multifunctional role in various cancer types and different stages. Here, to address prognostic significance of miR-218 in breast cancer, we investigate the expression profile of miR-218 and B-cell-specific Moloney murine leukemia virus integration site 1 ( BMI1) gene, as one of the putative targets of miR-218, in 33 paired breast tumors and their adjacent normal tissues with respect to the clinicopathological features of patients using quantitative real-time polymerase chain reaction. The correlation of both miR-218 and BMI1 gene expression with overall survival of breast cancer patients was also examined recruiting OncoLNC data portal. Finally, to better understand biological function of miR-218 in breast cancer, we performed in silico Gene Ontology and signaling pathway enrichment analysis on miR-218 targetome. According to our data, significant elevation of the expression of miR-218 and downregulation of BMI1 were observed in clinical breast cancer specimens compared with normal tissues ( p < 0.0001). The lower expression of miR-218 was associated with lymph node metastases, higher grades, and poorer prognosis (logrank p = 0.00988), whereas no significant difference in overall survival was observed between patients with higher and lower expression of BMI1 (logrank p = 0.254). These findings suggest that miR-218 expression profiling might be clinically applicable as a prognostic biomarker in breast cancer. In addition, our in silico enrichment analyses revealed that the association of miR-218 expression with breast cancer prognosis might be through its involvement in endocytosis and gap junction biological pathways.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/genética
Neoplasias da Mama Masculina/genética
Neoplasias da Mama/genética
MicroRNAs/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Neoplasias da Mama/patologia
Neoplasias da Mama Masculina/patologia
Feminino
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Estimativa de Kaplan-Meier
Metástase Linfática
Masculino
Meia-Idade
Gradação de Tumores
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (MIRN218 microRNA, human); 0 (MicroRNAs)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317698362


  10 / 2649 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28701264
[Au] Autor:Buckley EJ; Zahnd WE; Rea DJ; Mellinger JD; Ganai S
[Ad] Endereço:Department of Surgery, Southern Illinois University School of Medicine, Springfield, USA.
[Ti] Título:Impact of rural-urban status on survival after mastectomy without reconstruction versus mastectomy with reconstruction.
[So] Source:Am J Surg;214(4):645-650, 2017 Oct.
[Is] ISSN:1879-1883
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Disparities in access to care exist for breast cancer patients, including access to surgeons performing reconstruction. We hypothesized rural patients have delayed time to surgery after mastectomy with reconstruction with implications on survival. METHODS: An observational study was conducted using the National Cancer Database on patients with breast cancer from 2003 to 2007 who underwent mastectomy, with or without reconstruction from 2003 to 2007 (n = 90,319). RESULTS: Patients with, and without, reconstruction varied by demographics, facility type and stage. Time to surgery was longer for mastectomy with reconstruction. Unadjusted analysis demonstrated marginally decreased survival for rural patients undergoing mastectomy alone but not for mastectomy with reconstruction. Cox proportional hazards analysis revealed no significant differences by rural-urban status, but a survival advantage was seen after mastectomy with reconstruction, which persisted up to a delay of 180 days. CONCLUSION: Patients who underwent reconstruction had improved survival. Time to surgery is shorter for rural patients (for all types of mastectomy). We found no significant rural-urban disparity in survival.
[Mh] Termos MeSH primário: Neoplasias da Mama/cirurgia
Mamoplastia
Mastectomia
[Mh] Termos MeSH secundário: Idoso
Neoplasias da Mama Masculina/cirurgia
Feminino
Acesso aos Serviços de Saúde
Seres Humanos
Illinois/epidemiologia
Masculino
Meia-Idade
População Rural
Taxa de Sobrevida
Resultado do Tratamento
População Urbana
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE



página 1 de 265 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde